When the efficacy of BALB/c‐derived allogeneic NK cells was evaluated in C57BL/6 mice bearing MC38 tumors, we found that the intratumoral administration of allogeneic NK cells significantly slowed tumor growth when combined with the blockade of NKG2A and Qa‐1b. The gene discussed is KLRC1; the disease is neoplasm.